PremiumCompany AnnouncementsAbCellera Biologics Reports 2024 Financial Results AbCellera files automatic mixed securities shelf AbCellera Biologics Reports 2024 Financial Results and Growth PremiumThe FlyAbCellera expands collaboration with AbbVie AbCellera price target lowered to $4 from $5 at KeyBanc FDA revokes EUAs for some antibody treatments for COVID-19 PremiumPre-EarningsABCL Earnings Report this Week: Is It a Buy, Ahead of Earnings? AbCellera downgraded to Hold from Buy at Benchmark AbCellera Biologics Earnings Call and Corporate Presentation Update